Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Intern Med ; 56(20): 2785-2790, 2017 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-28924121

RESUMO

We herein describe the first known case of pleuritis caused by Mycobacterium kyorinense without pulmonary involvement. A 48-year-old man undergoing immunosuppressant therapy presented with cough and dyspnea. An accumulation of pleural fluid was noted; however, computed tomography revealed no pulmonary lesions. Cultures of the fluid yielded non-tuberculous mycobacteria, which was identified as Mycobacterium kyorinense. The patient recovered after 6 months of therapy with clarithromycin and moxifloxacin. Clinicians should be aware that Mycobacterium kyorinense can cause pleuritis without pulmonary involvement. When mycobacterial species are isolated from the pleural fluid, precise identification and drug susceptibility testing are warranted.


Assuntos
Infecções por Mycobacterium/complicações , Infecções por Mycobacterium/tratamento farmacológico , Pleurisia/complicações , Pleurisia/microbiologia , Claritromicina/uso terapêutico , Tosse , Dispneia , Exsudatos e Transudatos/microbiologia , Fluoroquinolonas/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Moxifloxacina , Pleurisia/diagnóstico por imagem , Pleurisia/tratamento farmacológico , Tomografia Computadorizada por Raios X
2.
Intern Med ; 55(17): 2463-7, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27580551

RESUMO

Desmoplastic small round cell tumor (DSRCT) is an aggressive mesenchymal tumor which primarily affects the abdomen. Even a multimodal approach rarely achieves durable remission and the optimal therapy for extended disease is unknown. We herein describe a rare case of DSRCT arising from the pleura in a 32-year-old man. Initial therapy, which included chemotherapy, surgery and radiotherapy, achieved a partial response for only two months. Although salvage chemotherapies had no effect, pazopanib treatment shrank the tumors and was well-tolerated on an outpatient basis. From the viewpoint of quality of life, pazopanib may therefore be a good therapeutic option for this aggressive disease.


Assuntos
Inibidores da Angiogênese/uso terapêutico , Tumor Desmoplásico de Pequenas Células Redondas/tratamento farmacológico , Neoplasias Pleurais/tratamento farmacológico , Pirimidinas/uso terapêutico , Sulfonamidas/uso terapêutico , Adulto , Terapia Combinada , Humanos , Indazóis , Masculino , Qualidade de Vida
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA